Trials that use: Risk difference
New to this method? Read the tutorial →
4,772 results
- Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer: primary endpoint results, effect estimate…
- Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: primary endpoint results,…
- Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CHOICESIndependent statistical analysis of Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cholecalciferol and Flu Vaccine in Treating Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Cholecalciferol and Flu Vaccine in Treating Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01561989).
- CHOOSEIndependent statistical analysis of Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects: primary endpoint results, effect estimate with confidence interval, sample-size…
- Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501: Complete Statistical AnalysisIndependent statistical analysis of Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chronic Liver Disease in Urea Cycle Disorders: Complete Statistical AnalysisIndependent statistical analysis of Chronic Liver Disease in Urea Cycle Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03721367).
- Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study: Complete Statistical AnalysisIndependent statistical analysis of Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China: Complete Statistical AnalysisIndependent statistical analysis of Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04853238).
- CHRONICLEIndependent statistical analysis of A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor): Complete Statistical AnalysisIndependent statistical analysis of Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00093964).
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CiloMecTIndependent statistical analysis of Pharmacodynamic Study of Cilostazol in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02554721).
- Circadian Brown Adipose Tissue Metabolism: Complete Statistical AnalysisIndependent statistical analysis of Circadian Brown Adipose Tissue Metabolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02285270).
- Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: Complete Statistical AnalysisIndependent statistical analysis of Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- CIRTIndependent statistical analysis of Cardiovascular Inflammation Reduction Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01594333).
- Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01026623).
- CJC-TraCIndependent statistical analysis of Criminal Justice Coordinated Transitional Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05376371).
- CL01-TIndependent statistical analysis of A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously: primary endpoint results, effect…
- Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CLARITYIndependent statistical analysis of A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CLASSICIIIndependent statistical analysis of Remission in Subjects With Crohn's Disease, 1 Year Phase: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00055497).
- Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant: Complete Statistical AnalysisIndependent statistical analysis of Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03380962).
- Cleansing Device for the Treatment of Scalp and Hair Conditions: Complete Statistical AnalysisIndependent statistical analysis of Cleansing Device for the Treatment of Scalp and Hair Conditions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05319444).
- CLEAR 2Independent statistical analysis of Combining Lesinurad With Allopurinol in Inadequate Responders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01493531).
- Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04245709).
- CLEVERIndependent statistical analysis of Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04767373).
- Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants: Complete Statistical AnalysisIndependent statistical analysis of Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis: Complete Statistical AnalysisIndependent statistical analysis of Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Clinical and Radiological Evaluation of Patients With DDD Following TLIF With 3-D Printed Titanium Cage: Complete Statistical AnalysisIndependent statistical analysis of Clinical and Radiological Evaluation of Patients With DDD Following TLIF With 3-D Printed Titanium Cage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Clinical Assessment of a Closed-loop Insulin Delivery System: Complete Statistical AnalysisIndependent statistical analysis of Clinical Assessment of a Closed-loop Insulin Delivery System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534013).
- Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals: Complete Statistical AnalysisIndependent statistical analysis of Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China: Complete Statistical AnalysisIndependent statistical analysis of Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China: primary endpoint results, effect estimate…
- Clinical Characterization of Symptomatic Populations: Complete Statistical AnalysisIndependent statistical analysis of Clinical Characterization of Symptomatic Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03319212).